Oxidized high-density lipoprotein reduces blood clot firmness

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 3, 2013, Pages 561-563

  Talens, S ^a   Malfliet, J J M C ^a   Leebeek, F W G ^a   Rijken, D C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HIGH DENSITY LIPOPROTEIN;

ARTICLE; BLOOD CLOT; BLOOD CLOTTING; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; BLOOD PLATELETS; FIBRIN; FIBRINOLYSIS; HUMANS; LIPOPROTEINS, LDL; THROMBELASTOGRAPHY; TIME FACTORS;

EID: 84874999859     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12125     Document Type: Article

References (19)

1. Talens S, Leebeek FW, Demmers JA, Rijken DC. Identification of fibrin clot-bound plasma proteins. PLoS ONE 2012; 7: e41966.
2. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
3. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 2006; 6: 721-30.
4. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870-6.
5. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410.
6. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
7. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-5.
8. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-9.
9. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-7.
10. Talens S, Hoekstra J, Dirkx SP, Murad SD, Trebicka J, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC. Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 908-14.
11. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
12. Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, Dahlback B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 2009; 284: 5896-904.
13. de Gaetano G, Bottecchia D, Vermylen J. Relaxation of retracted clots: a thrombelastographic study. Thromb Res 1974; 5: 431-5.
14. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100: 1781-5.
15. Valiyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, Podrez EA. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008; 111: 1962-71.
16. Takahashi Y, Chiba H, Matsuno K, Akita H, Hui SP, Nagasaka H, Nakamura H, Kobayashi K, Tandon NN, Jamieson GA. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Commun 1996; 222: 453-9.
17. Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, Seedorf U, Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1, 2-diacylglycerol and inositol 1, 4, 5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998; 18: 861-9.
18. Brodde MF, Korporaal SJ, Herminghaus G, Fobker M, Van Berkel TJ, Tietge UJ, Robenek H, Van Eck M, Kehrel BE, Nofer JR. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids. Atherosclerosis 2011; 215: 374-82.
19. Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008; 582: 778-84.